Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:42 PM
Ignite Modification Date:
2025-12-24 @ 4:42 PM
NCT ID:
NCT01302366
Eligibility Criteria:
Inclusion Criteria:
* Diagnosis of multiple myeloma based on standard criteria as follows:
Major Criteria
* Plasmacytomas on tissue biopsy
* Bone marrow plasmacytosis (\> 30% plasma cells)
* Monoclonal immunoglobulin (Ig) spike on serum electrophoresis (IgG \> 3.5 g/dL or IgA \> 2.0 g/dL); kappa or lambda light chain excretion \> 1 g/day on 24 hour urine protein electrophoresis
Minor Criteria
* Bone marrow plasmacytosis (10 to 30% plasma cells)
* Monoclonal immunoglobulin present but of lesser magnitude than given under major criteria
* Normal IgM \< 50 mg/dL, IgA \< 100 mg/dL, or IgG \< 600 mg/dL
Any of the following sets of criteria will confirm the diagnosis of Multiple Myeloma:
* Any two of the major criteria
* Major criterion 1 plus minor criterion b, c
* Major criterion 3 plus minor criterion a or c
* Minor criteria a, b and c
* Measurable disease, defined as a monoclonal immunoglobulin spike on serum electrophoresis of ≥ 1 g/dL and/or urine monoclonal immunoglobulin spike of ≥ 200 mg/24 hours.
* Non-secretors must have measurable protein by Freelite or measurable disease such as plasmacytoma to be eligible.
* Has asymptomatic disease, i.e., does not have hypercalcemia, renal insufficiency, anemia or bone lesions.
* Karnofsky performance status ≥ 80 (See Appendix B)
* Is infertile (i.e. surgically sterile or 12 months post-menopausal) or is practicing an adequate form of contraception, as judged by the investigator (i.e., birth control pills, double barrier method, abstinence, etc.)
* Age 18 years or older
* Has given voluntary written informed consent, prior to any study-related procedure not part of normal medical care, with the understanding that the patient may withdraw consent at any time without prejudice to future medical care.
Exclusion Criteria:
* Prior treatment for myeloma (symptomatic or asymptomatic).
* POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes)
* Plasma cell leukemia
* Patients with a history of thyroid problems.
* Receiving steroids \> the equivalent of 10 mg prednisone daily for other medical conditions, e.g., asthma, systemic lupus erythematosis, rheumatoid arthritis
* Infection not controlled by antibiotics
* Human Immunodeficiency Virus (HIV) infection. Patients should provide consent for HIV testing according to the institution's standard practice
* Known active hepatitis B or C
* New York Hospital Association (NYHA) Class III or IV heart failure or EKG evidence of acute ischemic disease
* Second malignancy requiring treatment in last 3 years
* Other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol
* Positive pregnancy test in women of childbearing potential
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01302366
Study Brief:
Protocol Section:
NCT01302366